From: Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
Target | Drug | Indication | Dose | ORR (%) | PFS (% at 24Â weeks; otherwise median) | OS (% at 1Â year; otherwise median or specified) | G3-G4 toxicity (%) |
---|---|---|---|---|---|---|---|
CTLA-4 | Melanoma | 3 mg/kg Q3W | [4.2–19] | 12.9% [2.63–2.9] months | [39.3–60.9]% | [15–27.3] | |
10 mg/kg Q3W | [11.1–15] | 18.9% [2.56–2.8] months | [44.2–54.3]% | [31–34] | |||
0.3Â mg/kg Q3W | 0 | 2.7% | 39.6% | Â | |||
RCC | 1Â mg/kg Q3W | 40.4 | 55.6% | 81% | 38.3 | ||
3Â mg/kg Q3W | 40.4 | 63.8% | 85% | 61.7 | |||
PD-1 | Melanoma | 0.1 mg/kg Q2W | [29–35] | [40–41]% |  | [0–5] | |
0.3 mg/kg Q2W | [19–28] | [31–35]% |  | [0–3] | |||
1 mg/kg Q2W | [30 31] | [45–51]% |  | [6–12] | |||
3 mg/kg Q2W | [31–43.7] | [39–55]% 6.9 months | 72.9% | [4–16.3] | |||
10 mg/kg Q2W | [9–20] | [30–45]% |  | [8–21] | |||
NSCLC | 1 mg/kg Q2W | [3–6] | [26–46]% | 33% | 15.2 | ||
3 mg/kg Q2W | [24–32] | [40–41]% | 56% | 13.5 | |||
10 mg/kg Q2W | [18–20] | [24–33]% | 38% | 13.6 | |||
RCC | 0.3Â mg/kg Q2W | 20 | 30% | 18.2% | 5 | ||
1 mg/kg Q2W | [24–28] | [47–50]% |  | 12 | |||
2Â mg/kg Q2W | 22 | 30% | 25.5% | 17 | |||
10Â mg/kg Q2W | 31 | 67% | 24.7% | 13 | |||
Mixed | 480Â mg Q4W | Â | Â | Â | 14.8 | ||
Melanoma | 2 mg/kg Q3W | [21–32.9] | 45% | 58% | [8–15] | ||
10 mg/kg Q2W | [33.7–52] |  |  | [13.3–22.8] | |||
10 mg/kg Q3W | [26–35.9] | 37% | 53% | [3.6–16] | |||
NSCLC | 2 mg/kg Q3W | [15–25] | 3.9 months | 10.4 months | 13 | ||
10 mg/kg Q2W | [19.3–21] |  |  | 9 | |||
10 mg/kg Q3W | [19.2–25] | 4 months | 12.7 months | [3.6–16] | |||
Hodgkin lymphoma | 10Â mg/kg Q2W | 65 | 69% | 100% at 24Â weeks | 22 | ||
200Â mg Q3W | 69 | Â | Â | 5.4 | |||
HNSCC | 10Â mg/kg Q2W | 18 | Â | Â | 23 | ||
200Â mg Q3W | 16 | 23% | 59% at 24Â weeks | 15 | |||
Urothelial cancer | 10Â mg/kg Q2W | 26 | 2Â months | 13Â months | 15 | ||
200Â mg Q3W | 24 | 2.1Â months | 10.3Â months | 15 | |||
Cemiplimab [32] | Cutaneaous SCC | 350Â mg Q3W | 41 | 10.4Â months | 76.1% | 39.3 | |
3Â mg/kg Q2W | 49 | 18.4Â months | 81.3% | 50.8 | |||
PD-L1 | RCC | 10 mg/kg Q2W | [51.4–58] | 13.8 months |  | [58–71.2] | |
Merkel cell carcinoma | 10Â mg/kg Q2W | 31.8 | 40% | 69% at 24Â weeks | 5 | ||
Mixed | 1Â mg/kg Q2W | 0 | Â | Â | 25 | ||
3Â mg/kg Q2W | 0 | Â | Â | 0 | |||
10Â mg/kg Q2W | 13 | Â | Â | 33 | |||
20Â mg/kg Q2W | 10 | Â | Â | 14 | |||
NSCLC | 1200Â mg Q3W | 14 | 2.8Â months | 13.8Â months | 13 | ||
1; 3; 10; 15, 20Â mg/kg Q3W | 23 | 45% | Â | Â | |||
Melanoma | 30 | 41% | Â | Â | |||
RCC | 14 | 48% | Â | Â | |||
Urothelial cancer | 1200Â mg Q3W | 15 | 2.1Â months | 7.9Â months | 16 | ||
SCLC | 1500Â mg Q3W | 68 | 45% | 54% | 22 | ||
Urothelial cancer | 10Â mg/kg Q2W | 31 | Â | Â | 5 | ||
NSCLC | 3Â mg/kg Q2W | 0 | Â | Â | 0 | ||
10Â mg/kg Q2W | 33 | Â | Â | 67 | |||
15Â mg/kg Q2W | 33 | Â | Â | 72 | |||
20Â mg/kg Q2W | 50 | Â | Â | 61 | |||
10 mg/kg Q2W | 0 | 17.2 months | 83.1% | [30.5–53] |